Short News


short news

Gout Diagnoses
Rising Worldwide

The prevalence of gout—a form of arthritis characterized by severe pain, redness, and tenderness in joints—increased across the world at an alarming rate from 1990 to 2017, according to an analysis published in Arthritis & Rheumatology. The analysis found that there were approximately 41.2 million prevalent cases of gout in 2017, with the rate of new diagnosed cases being 92 per 100,000 people, an increase of 5.5% from 1990.

Gout was more common in males and in older individuals. Also, the burden of gout was generally highest in developed regions and countries. High body mass index and impaired kidney function were risk factors for gout. The increasing trend of gout burden is most likely to continue as the global aging population is on the rise, said senior author Emma Smith, PhD, of The University of Sydney, in Australia. Attempts to lessen the disease onset and future burden of gout require better awareness, especially of risk factors, and early diagnosis and treatment.


Early Clinical Trial Tests 
Treatment Strategy for PC

Pancreatic cancer carries a poor prognosis, and it often goes undetected until advanced stages. A new BJS (British Journal of Surgery) study indicates that a certain cocktail of chemotherapy drugs may be a safe and effective treatment option for patients with a metastatic form of the disease.

The study, which was an early-phase 46-patient trial intended to provide preliminary results regarding safety and efficacy, tested a strategy involving injections of paclitaxel into the abdomen and injections of gemcitabine and nab-paclitaxel (a combination of paclitaxel and a protein called albumin) into the blood. The treatment had acceptable toxicities, and patients had a median survival time of 14.5 months, with a 1-year survival rate of 60.9%.

Now, a phase 3 study to compare survival outcomes between this therapy and standard chemotherapy has been launched, said senior author Sohei Satoi, MD, of Kansai Medical University, in Japan.


HCPs recommended 
for Civil Awards by
Punjab Government

LAHORE: The Government of Punjab has recommended the names of following healthcare professionals for Civil Awards in recognition of their devoted services and dedication to their profession during the COVID19 Pandemic. Those recommended are as under:

1. Late Prof. Dr. Mustafa Kamal Pasha Shaheed,
Vice Chancellor,
Nishtar Medical University, Multan. Shaheed on July 15th 2020.
Recommended for: Nishan-e-Imtiaz

2. Prof. (Retd.) Dr. Mahmood Shoukat, Chairman CEAG,
Corona Expert Advisory Group (CEAG),
Recommended for: Sitar-e-Imtiaz

3. Prof. Dr. Asad Alam,
Chief Executive Officer,
Mayo Hospital, Lahore.
Recommended for: Sitar-e-Imtiaz

4. Prof. Dr. Muhammad Umar,
Vice Chancellor,
RMU, Rawalpindi.
Recommended for: Tamgha-e-Imtiaz

5. Prof. Dr. Javaid Raza Gardezi,
Chairman, Board of Governor,
Pakistan Kidney & Liver Institute & Research Center (PKLI).
Recommended for: Tamgha-e-Imtiaz

6. Dr. Khalid Naz,
Consultant Anesthetist,
Government General Hospital,
Ghulam Muhammad Abad, Faisalabad.
Recommended for: Tamgha-e-Imtiaz

Nurses and Paramedics recommended for Tamgha-e-Imtiaz include the following:

7. Shaziz Latif,
Charge Nurse,

8. Muhammad Tariq Saeed,
ECG Technician,
Mayo Hospital, Lahore.

9. Katherine Siddique,
Head Nurse,
Lahore General Hospital,

10. Shahida Jabeen Maham,
Charge Nurse,
Services Hospital, Lahore City, Lahore.

11. Samual S/o Khursheed Massih,
Allama Iqbal Memorial Hospital, Sialkot.

12. Komal Nayab,
Nishtar Medical University Hospital, Multan.

It is not clear how comprehensive the above list is and whether the authorities did consult with the professional bodies like PMA and PMA to know their views before finalizing this list recommended for Civil Awards. So far no such nomination has been made by other provincial governments.

Rheumatoid Arthritis Linked
to a Lower Risk of Type 2 Diabetes

A recent analysis of a US commercial insurance database found that adults with rheumatoid arthritis had a lower risk of developing type 2 diabetes than other individuals, including those with other types of arthritis.

The analysis, which is published in Arthritis Care & Research, compared adults with rheumatoid arthritis with four other groups: individuals from the general population without rheumatoid arthritis, individuals with hypertension, individuals with osteoarthritis, and individuals with psoriatic arthritis. A total of 449,327 people were included.

During the median of 1.6 years of follow-up, the rate of type 2 diabetes development was lowest in the rheumatoid arthritis group (7.0 per 1,000 people per year) and highest (12.3 per 1,000 people per year) in the hypertension group. After adjustments, rheumatoid arthritis was associated with a 24% to 35% lower risk of developing type 2 diabetes compared with the four other groups.

While systemic inflammation in rheumatoid arthritis increases the risk of cardiovascular disease, our findings unexpectedly show that having rheumatoid arthritis itself does not confer an increased risk of type 2 diabetes compared with four different comparator groups, said senior author Seoyoung C. Kim, MD, ScD, MSCE, of Harvard Medical School. Since all rheumatoid arthritis patients included in our study were treated with at least one disease-modifying antirheumatic drug, our study is unable to test the association between no treatments or under treatment for rheumatoid arthritis and risk of type 2 diabetes.


© Professional Medical Publications. All rights reserved.